Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1121

1.

Impact of comorbidity on treatment response to paroxetine in pediatric obsessive-compulsive disorder: is the use of exclusion criteria empirically supported in randomized clinical trials?

Geller DA, Biederman J, Stewart SE, Mullin B, Farrell C, Wagner KD, Emslie G, Carpenter D.

J Child Adolesc Psychopharmacol. 2003;13 Suppl 1:S19-29.

PMID:
12880497
2.

Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics.

McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH.

Arch Gen Psychiatry. 1994 Apr;51(4):302-8.

PMID:
8161290
3.

A naturalistic exploratory study of the impact of demographic, phenotypic and comorbid features in pediatric obsessive-compulsive disorder.

Masi G, Millepiedi S, Perugi G, Pfanner C, Berloffa S, Pari C, Mucci M, Akiskal HS.

Psychopathology. 2010;43(2):69-78. doi: 10.1159/000274175. Epub 2010 Jan 9.

PMID:
20068377
4.

Tics moderate treatment outcome with sertraline but not cognitive-behavior therapy in pediatric obsessive-compulsive disorder.

March JS, Franklin ME, Leonard H, Garcia A, Moore P, Freeman J, Foa E.

Biol Psychiatry. 2007 Feb 1;61(3):344-7.

PMID:
17241830
5.

Paroxetine treatment in children and adolescents with obsessive-compulsive disorder: a randomized, multicenter, double-blind, placebo-controlled trial.

Geller DA, Wagner KD, Emslie G, Murphy T, Carpenter DJ, Wetherhold E, Perera P, Machin A, Gardiner C.

J Am Acad Child Adolesc Psychiatry. 2004 Nov;43(11):1387-96.

PMID:
15502598
6.

Quality of life outcomes in patients with obsessive-compulsive disorder: relationship to treatment response and symptom relapse.

Hollander E, Stein DJ, Fineberg NA, Marteau F, Legault M.

J Clin Psychiatry. 2010 Jun;71(6):784-92. doi: 10.4088/JCP.09m05911blu. Epub 2010 May 4.

PMID:
20492845
7.

Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine.

Hollander E, Allen A, Steiner M, Wheadon DE, Oakes R, Burnham DB; Paroxetine OCD Study Group.

J Clin Psychiatry. 2003 Sep;64(9):1113-21.

PMID:
14628989
8.
9.

Paroxetine open-label treatment of pediatric outpatients with obsessive-compulsive disorder.

Rosenberg DR, Stewart CM, Fitzgerald KD, Tawile V, Carroll E.

J Am Acad Child Adolesc Psychiatry. 1999 Sep;38(9):1180-5.

PMID:
10504818
10.

Comorbidity of obsessive-compulsive disorder and attention-deficit/hyperactivity disorder in referred children and adolescents.

Masi G, Millepiedi S, Mucci M, Bertini N, Pfanner C, Arcangeli F.

Compr Psychiatry. 2006 Jan-Feb;47(1):42-7.

PMID:
16324901
11.

Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study.

Kordon A, Wahl K, Koch N, Zurowski B, Anlauf M, Vielhaber K, Kahl KG, Broocks A, Voderholzer U, Hohagen F.

J Clin Psychopharmacol. 2008 Oct;28(5):550-4. doi: 10.1097/JCP.0b013e318185e735.

PMID:
18794652
12.

Comparison of clinical characteristics and comorbidity in schizophrenia patients with and without obsessive-compulsive disorder: schizophrenic and OC symptoms in schizophrenia.

Poyurovsky M, Kriss V, Weisman G, Faragian S, Kurs R, Schneidman M, Fuchs C, Weizman A, Weizman R.

J Clin Psychiatry. 2003 Nov;64(11):1300-7.

PMID:
14658943
13.

[Efficacy and tolerability of escitalopram in anxiety disorders: a review].

Pelissolo A.

Encephale. 2008 Sep;34(4):400-8. doi: 10.1016/j.encep.2008.04.004. Epub 2008 Aug 15. Review. French.

PMID:
18922243
14.
15.

A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder.

Wagner KD, Berard R, Stein MB, Wetherhold E, Carpenter DJ, Perera P, Gee M, Davy K, Machin A.

Arch Gen Psychiatry. 2004 Nov;61(11):1153-62.

PMID:
15520363
16.

Remission status after long-term sertraline treatment of pediatric obsessive-compulsive disorder.

Wagner KD, Cook EH, Chung H, Messig M.

J Child Adolesc Psychopharmacol. 2003;13 Suppl 1:S53-60.

PMID:
12880500
17.

Paroxetine in the treatment of obsessive-compulsive disorder: randomized, double-blind, placebo-controlled study in Japanese patients.

Kamijima K, Murasaki M, Asai M, Higuchi T, Nakajima T, Taga C, Matsunaga H.

Psychiatry Clin Neurosci. 2004 Aug;58(4):427-33.

18.
19.

A naturalistic study of referred children and adolescents with obsessive-compulsive disorder.

Masi G, Millepiedi S, Mucci M, Bertini N, Milantoni L, Arcangeli F.

J Am Acad Child Adolesc Psychiatry. 2005 Jul;44(7):673-81.

PMID:
15968236
20.

Personality changes in adult subjects with major depressive disorder or obsessive-compulsive disorder treated with paroxetine.

Brody AL, Saxena S, Fairbanks LA, Alborzian S, Demaree HA, Maidment KM, Baxter LR Jr.

J Clin Psychiatry. 2000 May;61(5):349-55.

PMID:
10847309

Supplemental Content

Support Center